Information Provided By: 
Fly News Breaks for August 10, 2015
INO
Aug 10, 2015 | 13:49 EDT
Stifel analyst Thomas Shrader said he likes Inovio's (INO) broad partnership with MedImmune (MEDI) to develop INO-3112 in combination with Medimmune's collection of IO molecules. Shrader believes Inovio's reach into oncology based on DNA-based vaccines combined with delivery of IL-12 is nearly unlimited. The firm's analyst said the deal makes sense given reasonable economics and a partner with broad experience in the vaccine space. Shrader rates Inovio a Buy with a $19 price target on shares.
News For INO From the Last 2 Days
There are no results for your query INO
